170 related articles for article (PubMed ID: 16978199)
41. High-grade carcinomas of the breast showing patterns of mixed ductal and myoepithelial differentiation (including myoepithelial cell-rich carcinoma of the breast).
Coyne JD; Dervan PA; Barr L
Histopathology; 2004 Jun; 44(6):580-4. PubMed ID: 15186273
[TBL] [Abstract][Full Text] [Related]
42. Neuroendocrine carcinomas of the breast.
Rovera F; Masciocchi P; Coglitore A; La Rosa S; Dionigi G; Marelli M; Boni L; Dionigi R
Int J Surg; 2008; 6 Suppl 1():S113-5. PubMed ID: 19167937
[TBL] [Abstract][Full Text] [Related]
43. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P
Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
[TBL] [Abstract][Full Text] [Related]
44. Cytokeratin expression profiles in thyroid carcinomas.
Lam KY; Lui MC; Lo CY
Eur J Surg Oncol; 2001 Nov; 27(7):631-5. PubMed ID: 11669590
[TBL] [Abstract][Full Text] [Related]
45. Differential expression of mucin core proteins and keratins in apocrine carcinoma, extramammary Paget's disease and apocrine nevus.
Miyamoto T; Inoue S; Adachi K; Takada R
J Cutan Pathol; 2009 May; 36(5):529-34. PubMed ID: 19476520
[TBL] [Abstract][Full Text] [Related]
46. BigH3 protein expression as a marker for breast cancer.
Calaf GM; Echiburú-Chau C; Zhao YL; Hei TK
Int J Mol Med; 2008 May; 21(5):561-8. PubMed ID: 18425347
[TBL] [Abstract][Full Text] [Related]
47. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
Tamas EF; Epstein JI
Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
[TBL] [Abstract][Full Text] [Related]
48. Prolactin receptor expression in gynaecomastia and male breast carcinoma.
Ferreira M; Mesquita M; Quaresma M; André S
Histopathology; 2008 Jul; 53(1):56-61. PubMed ID: 18613925
[TBL] [Abstract][Full Text] [Related]
49. CK5 is more sensitive than CK5/6 in identifying the "basal-like" phenotype of breast carcinoma.
Bhargava R; Beriwal S; McManus K; Dabbs DJ
Am J Clin Pathol; 2008 Nov; 130(5):724-30. PubMed ID: 18854264
[TBL] [Abstract][Full Text] [Related]
50. Vimentin expression in breast carcinomas.
Niveditha SR; Bajaj P
Indian J Pathol Microbiol; 2003 Oct; 46(4):579-84. PubMed ID: 15025348
[TBL] [Abstract][Full Text] [Related]
51. Cytokeratin subtyping in chordomas and the fetal notochord: an immunohistochemical analysis of aberrant expression.
Naka T; Iwamoto Y; Shinohara N; Chuman H; Fukui M; Tsuneyoshi M
Mod Pathol; 1997 Jun; 10(6):545-51. PubMed ID: 9195570
[TBL] [Abstract][Full Text] [Related]
52. Basal carcinoma of the breast revisited: an old entity with new interpretations.
Korsching E; Jeffrey SS; Meinerz W; Decker T; Boecker W; Buerger H
J Clin Pathol; 2008 May; 61(5):553-60. PubMed ID: 18326009
[TBL] [Abstract][Full Text] [Related]
53. Basal phenotype: a powerful prognostic factor in small screen-detected invasive breast cancer with long-term follow-up.
Evans AJ; Rakha EA; Pinder SE; Green AR; Paish C; Ellis IO
J Med Screen; 2007; 14(4):210-4. PubMed ID: 18078567
[TBL] [Abstract][Full Text] [Related]
54. Impact of immunohistochemical markers, CK5/6 and E-cadherin on diagnostic agreement in non-invasive proliferative breast lesions.
MacGrogan G; Arnould L; de Mascarel I; Vincent-Salomon A; Penault-Llorca F; Lacroix-Triki M; Bibeau F; Baranzelli MC; Fridman V; Antoine M; Bécette V; Brouste V; Jacquemier J; Mathoulin-Pélissier S;
Histopathology; 2008 May; 52(6):689-97. PubMed ID: 18397281
[TBL] [Abstract][Full Text] [Related]
55. C-kit expression in high-risk breast cancer subgroup treated with high-dose or conventional dose-dense chemotherapy.
Diallo R; Ting E; Gluz O; Herr A; Schütt G; Geddert H; Mohrmann S; Gabbert HE; Nitz U; Poremba C
Verh Dtsch Ges Pathol; 2006; 90():177-85. PubMed ID: 17867595
[TBL] [Abstract][Full Text] [Related]
56. Identification of a basal-like subtype of breast ductal carcinoma in situ.
Livasy CA; Perou CM; Karaca G; Cowan DW; Maia D; Jackson S; Tse CK; Nyante S; Millikan RC
Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468
[TBL] [Abstract][Full Text] [Related]
57. Cytokeratin contents of basal cell carcinoma, epidermis overlying tumour, and associated stromal amyloidosis: an immunohistochemical study.
Apaydin R; Gürbüz Y; Bayramgürler D; Bilen N
Amyloid; 2005 Mar; 12(1):41-7. PubMed ID: 16076610
[TBL] [Abstract][Full Text] [Related]
58. Immunohistochemical visualisation of cathepsin-D expression in breast cancer.
Barthell E; Mylonas I; Shabani N; Kunze S; Kuhn C; Jeschke U; Friese K
Anticancer Res; 2007; 27(4A):2035-9. PubMed ID: 17649818
[TBL] [Abstract][Full Text] [Related]
59. Over-expression of metallothionein predicts chemoresistance in breast cancer.
Yap X; Tan HY; Huang J; Lai Y; Yip GW; Tan PH; Bay BH
J Pathol; 2009 Mar; 217(4):563-70. PubMed ID: 19116991
[TBL] [Abstract][Full Text] [Related]
60. Immunohistochemical characterization of cytokeratins in the abnormal corneal endothelium of posterior polymorphous corneal dystrophy patients.
Jirsova K; Merjava S; Martincova R; Gwilliam R; Ebenezer ND; Liskova P; Filipec M
Exp Eye Res; 2007 Apr; 84(4):680-6. PubMed ID: 17289024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
